Resources from the same session
Welcome and Introduction
Presenter: Patrizia Giannatempo, Alison Birtle
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Unveiling real-world evidence: Exploring the PSA Response in mHSPC
Presenter: Alison Birtle
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Efficacy and QoL in mHSPC – finding the right balance
Presenter: Alejo Rodriguez-Vida
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
The significance of BRCA1/2 mutations in mCRPC outcomes
Presenter: Elena Verzoni
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Panel discussion
Presenter: Patrizia Giannatempo, Alison Birtle, Alejo Rodriguez-Vida, Elena Verzoni
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
FGFR testing: Why, how, when?
Presenter: Viktor Gruenwald
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Optimising patient care: Managing adverse events
Presenter: Simon Crabb, Viktor Gruenwald
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast
Summary and Close
Presenter: Patrizia Giannatempo, Alison Birtle
Session: Johnson & Johnson - Optimising the personalisation of GU cancer care
Resources:
Webcast